Can darolutamide cause serious side effects?

Can darolutamide cause serious side effects?
Yes. Darolutamide can cause serious side effects, including heart rhythm problems, seizures, falls, fractures, and liver toxicity.

How common are serious heart issues with darolutamide?
In clinical trials, heart failure occurred in about 2 percent of patients, and some developed abnormal heart rhythms. Patients with existing heart disease or those taking certain other medicines face higher risk.

What seizure risk does darolutamide carry?
Seizures are rare but documented. The drug label warns patients with a history of seizures or those taking medicines that lower the seizure threshold to use caution.

Do falls and fractures occur more often with darolutamide?
Yes. Falls affected 4 percent of patients and fractures 4 percent in trials. These events are more likely in older men or those with bone weakness.

Can darolutamide damage the liver?
Liver enzyme elevations occurred in roughly 5 percent of patients. Severe liver injury is uncommon, but monitoring of liver function is recommended during treatment.

Does darolutamide interact with other medicines that increase side-effect risk?
Yes. Strong CYP3A4 inhibitors and inducers can raise or lower darolutamide levels, changing the chance of side effects. Patients should review all medicines with their doctor before starting therapy.

When do most serious side effects appear?
Most cardiac and seizure events were reported within the first six months of treatment, while fractures and falls accumulated over longer periods of use.

How do these risks compare with other androgen-receptor inhibitors?
Darolutamide has a lower reported seizure rate than enzalutamide, but similar rates of falls and fractures. Direct head-to-head safety data remain limited.

What should patients do if they notice symptoms?
Contact their doctor immediately for chest pain, shortness of breath, dizziness, sudden confusion, yellowing of the skin, or unexplained falls. Early reporting often leads to dose adjustments or temporary pauses in treatment.

Where can patients and prescribers find the latest safety updates?
The prescribing information and ongoing post-marketing reports are available on DrugPatentWatch.com.